Non-Opioid Pain Therapeutics Summit

For more than two decades, biopharma has struggled to develop safe and effective non-opioid pain therapies. With Vertex’s recent approval marking a long-awaited breakthrough, the momentum has reached a critical point for bringing non-opioid pain therapeutics to market.

Whether advancing NaV-targeting drugs or pursuing novel pain mechanisms, non-opioid therapeutics are now in the clinical spotlight and the next 12 months promise to be transformative.

The Non-Opioid Pain Therapeutics Summit provides a dedicated platform to harness that momentum. Attendees will be learning from companies with approvals such as Tonix, exploring late-stage strategies from innovators like Latigo and Algiax, and uncovering discovery breakthroughs from Nocion and Axonis. Join 70+ discovery, preclinical, translational and clinical industry-based experts driving the future of non-opioid pain therapies across diverse pain indications.


URLs:
Website: https://go.evvnt.com/3249980-0?pid=2874
Brochure: https://go.evvnt.com/3249980-3?pid=2874

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 3497.00,
Drug Developer Pricing - Conference Only: USD 2599.00,
Academic Pricing - Conference + Workshop Day: USD 2897.00,
Academic Pricing - Conference Only: USD 2199.00,
Service Provider Pricing - Conference + Workshop Day: USD 5097.00,
Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Michele Curatolo, Chief Medical Officer and Professor of Anesthesiology and Pain Medicine, 4E Therapeutics and University of Washington, Asli Chrisensen, Director Search and Evaluation, Abbvie, Guido Koopmans, Chief Scientific Officer, Algiax Pharmaceuticals, Lizandra Marcondes, Senior Vice President, Medical Affairs and Drug Safety, Avertias Pharma, Shane Hegarty, Chief Scientific Officer, Axonis Therapeutics, Clifford Woolf, Director FM Kirby Neurobiology Centre, Boston Children's Hospital, Bryan Moyer, Senior Vice President - Discovery, Latigo Biotherapeutics, John Markman, Vice President, Global Pain, Eli Lilly and Co., Simon Westbrook, Chief Scientific Officer, Levicept, Craig Granowitz, Chief Medical Officer, Lexicon Pharmaceuticals, Darrell Henze, Executive Director, Merck and Co, Bruce Bean, Professor, Neurobiology at Harvard Medical School, James Ellis, Chief Scientific Officer, Nocion Therapeutics, Christopher Adams, Executive Director Search and Evaluation, Novartis, Heikki Mansikka, Vice President Pain Therapy Areas, Orion Pharma, Hongkang Zhang, Senior Director - Pain Therapeutic Lead, Quiver Bioscience, Gregory Sullivan, Chief Medical Officer, Tonix Pharmaceuticals, James Hackworth, Chief Business Officer, Tris Pharma, Jennifer Gewandter, Associate Professor, University of Rochester Medical Center